Thanking My Favorite iHub Posters and Introducing Myself
Hi everyone:
My name is OncoJock, and I've been writing about advances in cancer medicine since 2009. I bought my first share of NWBO in March of 2021, after writing an educational needs assessment about promising therapies in glioblastoma. I've been reading posts on this board since shortly after I first bought shares. My wife and I now hold shares in four different accounts, and our overall cost basis is $1.27.
Before I write anything else, I wish to thank the people who've been sharing such a wealth of knowledge, experience, and perspective here with their fellow shareholders. In particular, I wish to thank the following iHubbers:
ATLnsider
Flipper44
Skitahoe
Vikinginvest
Hoffman6383
a e kusterer
Thermo
Biosectinvestor
SentimentStocks
Lykiri
Poor Man
Kabunushi
Bright Boy
Basin Street Blues
Hope4Patients
Sojourner55
Doc_Logic
The Danish Dude
I also wish to thank our volunteer moderators XenaLives, sentiment_stocks, HappyLibrarian, BigFootOR, JerryCampbell and Dr. Bala for working so hard to keep this board a pleasant, useful, intellectually stimulating, educational, and (potentially) financially rewarding place to spend our time, do our due diligence, and learn. I've learned a great deal by reading posts here over the past year, and I hope to be able to make my own helpful contributions in the days, weeks, and months ahead.
I also want to say what a pleasure it has been to watch the recent presentations by Dr. Mulholland, Dr. Ashkan, and Dr. Liau regarding results of the phase 3 trial of DCVax-L. I'm proud to own shares in a company that is making such important progress to help patients by developing an effective treatment for such a nasty tumor type as GBM. While I'm as impatient as many of the rest of you when it comes to waiting for the peer-reviewed journal article, news of submissions to regulatory authorities, and announcement of a date for the annual shareholders meeting, it has still been marvelous to witness the success NWBO is enjoying when so many other companies have tried and failed to improve outcomes for patients with both newly diagnosed and recurrent disease.
Finally, I wish to thank my late father, who was a prominent physician as well as a savvy investor in several life science and pharmaceutical companies. Dad left me a grubstake to invest, and he gave me this memorable piece of advice: "Don't risk more than you can afford to lose." I try to remember his prudent approach when it comes to buying shares in NWBO, or any other company.
I look forward to reading more of your posts and writing some of my own.
More later.
-- OncoJock
